Tyra Biosciences (NASDAQ:TYRA) Reaches New 52-Week High at $22.05

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as $22.05 and last traded at $21.83, with a volume of 42592 shares. The stock had previously closed at $20.78.

Wall Street Analyst Weigh In

Several research firms have recently commented on TYRA. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. Oppenheimer restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. Finally, Wedbush restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, July 3rd.

Tyra Biosciences Stock Performance

The company has a market cap of $1.07 billion, a P/E ratio of -12.49 and a beta of 1.01. The firm’s fifty day moving average is $18.18 and its two-hundred day moving average is $17.20.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.11. On average, equities research analysts expect that Tyra Biosciences, Inc. will post -1.71 EPS for the current year.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, COO Daniel Bensen sold 3,502 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $20.00, for a total transaction of $70,040.00. Following the completion of the transaction, the chief operating officer now owns 427,981 shares of the company’s stock, valued at approximately $8,559,620. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Several hedge funds have recently made changes to their positions in TYRA. Wellington Management Group LLP raised its position in shares of Tyra Biosciences by 18.5% during the 3rd quarter. Wellington Management Group LLP now owns 94,112 shares of the company’s stock valued at $1,296,000 after buying an additional 14,676 shares in the last quarter. Federated Hermes Inc. raised its position in shares of Tyra Biosciences by 1,244.2% during the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after buying an additional 1,916 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Tyra Biosciences by 53.4% during the 4th quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock valued at $696,000 after buying an additional 17,490 shares in the last quarter. AJOVista LLC purchased a new stake in shares of Tyra Biosciences during the 4th quarter valued at about $59,000. Finally, Kynam Capital Management LP purchased a new stake in shares of Tyra Biosciences during the 4th quarter valued at about $4,712,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.